{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:20:08Z","timestamp":1788542408557,"version":"build-2803163510"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s11095-026-04126-z","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:21:16Z","timestamp":1780600876000},"page":"2393-2406","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Acting Antimalarial Drug Delivery Systems for Chemoprophylaxis: Formulation Strategies and Routes of Administration"],"prefix":"10.1007","volume":"43","author":[{"given":"Yogesh","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal Babasaheb","family":"Galave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3856-869X","authenticated-orcid":false,"given":"Anil B.","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"1","key":"4126_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40506-024-00279-w","volume":"17","author":"A Kumari","year":"2024","unstructured":"Kumari A, et al. From Lab Bench to Bedside: Advancing Malaria Treatments through Research, Patents, and Clinical Trials. Curr Treat Options Infect Dis. 2024;17(1):1\u201326. https:\/\/doi.org\/10.1007\/s40506-024-00279-w.","journal-title":"Curr Treat Options Infect Dis"},{"key":"4126_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.08.043","author":"AR Bhide","year":"2023","unstructured":"Bhide AR, Surve DH, Jindal AB. Nanocarrier based active targeting strategies against erythrocytic stage of malaria. J Control Release. 2023. https:\/\/doi.org\/10.1016\/j.jconrel.2023.08.043.","journal-title":"J Control Release"},{"key":"4126_CR3","unstructured":"\u201cMalaria.\u201d [Online]. Available:\u00a0https:\/\/www.who.int\/data\/gho\/data\/themes\/malaria. Accessed 18 Apr 2026."},{"key":"4126_CR4","unstructured":"WHO. \u201cGlobal technical strategy for malaria 2016\u20132030,\u201d World Heal Organ; 2015. p. 1\u201335. [Online]. Available:\u00a0http:\/\/apps.who.int\/iris\/bitstream\/10665\/176712\/1\/9789241564991_eng.pdf?ua=1. Accessed 04 Nov 2025."},{"key":"4126_CR5","unstructured":"\u201cMeat consumption in India | Data For India.\u201d [Online]. Available:\u00a0https:\/\/www.dataforindia.com\/malaria-in-india\/. Accessed 04 Nov 2025."},{"issue":"6","key":"4126_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/BMJGH-2022-008431","volume":"7","author":"S Sharma","year":"2022","unstructured":"Sharma S, Verma R, Yadav B, Kumar A, Rahi M, Sharma A. What India can learn from globally successful malaria elimination programmes. BMJ Global Health. 2022;7(6):8431. https:\/\/doi.org\/10.1136\/BMJGH-2022-008431.","journal-title":"BMJ Global Health"},{"key":"4126_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-005391","author":"R Ranjha","year":"2021","unstructured":"Ranjha R, Sharma A. Forest malaria: the prevailing obstacle for malaria control and elimination in India. BMJ Glob Health. 2021. https:\/\/doi.org\/10.1136\/bmjgh-2021-005391.","journal-title":"BMJ Glob Health"},{"key":"4126_CR8","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.2147\/DDDT.S265602","volume":"14","author":"TM Belete","year":"2020","unstructured":"Belete TM. Recent progress in the development of new antimalarial drugs with novel targets. Drug Des Devel Ther. 2020;14:3875\u201389. https:\/\/doi.org\/10.2147\/DDDT.S265602.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"4126_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2875-12-265","volume":"12","author":"K Vliegenthart-Jongbloed","year":"2013","unstructured":"Vliegenthart-Jongbloed K, De Mendon\u00e7a Melo M, Van Wolfswinkel ME, Koelewijn R, Van Hellemond JJ, Van Genderen PJ. Severity of imported malaria: protective effect of taking malaria chemoprophylaxis. Malar J. 2013;12(1):1\u201310. https:\/\/doi.org\/10.1186\/1475-2875-12-265.","journal-title":"Malar J"},{"key":"4126_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00059-07","author":"P Schlagenhauf","year":"2008","unstructured":"Schlagenhauf P, Petersen E. Malaria chemoprophylaxis: strategies for risk groups. Clin Microbiol Rev. 2008. https:\/\/doi.org\/10.1128\/CMR.00059-07.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"4126_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-023-04794-x","volume":"22","author":"M Kotepui","year":"2023","unstructured":"Kotepui M, Kotepui KU, Masangkay FR, Wilairatana P. Evidence of malarial chemoprophylaxis among travellers who died from malaria: a systematic review and meta-analysis. Malar J. 2023;22(1):1\u201311. https:\/\/doi.org\/10.1186\/s12936-023-04794-x.","journal-title":"Malar J"},{"key":"4126_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-9-357","author":"P Schlagenhauf","year":"2010","unstructured":"Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Rhein HG. The position of mefloquine as a 21st century malaria chemoprophylaxis. Malar J. 2010. https:\/\/doi.org\/10.1186\/1475-2875-9-357.","journal-title":"Malar J"},{"issue":"11","key":"4126_CR13","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.3201\/eid1511.091147","volume":"15","author":"P Gautret","year":"2009","unstructured":"Gautret P, et al. \u201cMulticenter EuroTravNet\/GeoSentinel study of travel-related infectious diseases in Europe,.\u201d Emerg Infect Dis. 2009;15(11):1783\u201390. https:\/\/doi.org\/10.3201\/eid1511.091147.","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"4126_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1086\/321817","volume":"33","author":"KC Kain","year":"2001","unstructured":"Kain KC, Shanks GD, Keystone JS. Malaria chemoprophylaxis in the age of drug resistance. I. currently recommended drug regimens. Clin Infect Dis. 2001;33(2):226\u201334. https:\/\/doi.org\/10.1086\/321817.","journal-title":"Clin Infect Dis"},{"key":"4126_CR15","unstructured":"fda and cder. \u201cARALEN \u00ae CHLOROQUINE PHOSPHATE, USP\u201d. [Online]. Available:\u00a0https:\/\/www.cdc.gov\/. Accessed 21 Nov 2025."},{"key":"4126_CR16","unstructured":"CDC. \u201cChoosing a Drug to Prevent Malaria | Malaria | CDC.\u201d. [Online]. Available:\u00a0https:\/\/www.cdc.gov\/malaria\/hcp\/drug-malaria\/index.html. Accessed 21 Nov 2025."},{"key":"4126_CR17","unstructured":"Ridpath AD, Wallender E. \u201cMalaria | Yellow Book | CDC.\u201d. [Online]. Available:\u00a0https:\/\/www.cdc.gov\/yellow-book\/hcp\/travel-associated-infections-diseases\/malaria.html#cdc_report_pub_study_section_5-epidemiology. Accessed 21 Nov 2025."},{"key":"4126_CR18","unstructured":"\u201cInternational travel and health: module 3: malaria.\u201d Accessed: Nov. 21, 2025. [Online]. Available: https:\/\/www.who.int\/publications\/i\/item\/9789240102286#cms."},{"key":"4126_CR19","unstructured":"FDA. \u201cVibramycin Calcium (doxycycline calcium oral suspension, USP) oral suspension SYRUP; Vibramycin Hyclate (doxycycline hyclate capsules, USP) CAPSULES; Vibramycin Monohydrate (doxycycline monohydrate) for ORAL SUSPENSION; Vibra-Tabs (doxycycline hyclate tab.\u201d [Online]. Available:\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/050006s092,050007s034,050480s058,050533s047lbl.pdf. Accessed 21 Nov 2025."},{"key":"4126_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.09.010","author":"W Zhou","year":"2020","unstructured":"Zhou W, Wang H, Yang Y, Chen ZS, Zou C, Zhang J. Chloroquine against malaria, cancers and viral diseases. Drug Discov Today. 2020. https:\/\/doi.org\/10.1016\/j.drudis.2020.09.010.","journal-title":"Drug Discov Today"},{"key":"4126_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.tiv.2019.01.008","volume":"56","author":"KRHM Oliveira","year":"2019","unstructured":"Oliveira KRHM, et al. \u201cAscorbic acid prevents chloroquine-induced toxicity in inner glial cells,.\u201d Toxicol In Vitro. 2019;56:150\u20135. https:\/\/doi.org\/10.1016\/j.tiv.2019.01.008.","journal-title":"Toxicol In Vitro"},{"key":"4126_CR22","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1101448","author":"MWP Tsang-A-Sjoe","year":"2015","unstructured":"Tsang-A-Sjoe MWP, Bultink IEM. Systemic lupus erythematosus: review of synthetic drugs. Expert Opin Pharmacother. 2015. https:\/\/doi.org\/10.1517\/14656566.2015.1101448.","journal-title":"Expert Opin Pharmacother"},{"key":"4126_CR23","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565150-00003","author":"GD Shanks","year":"2005","unstructured":"Shanks GD, Edstein MD. Modern malaria chemoprophylaxis. Drugs. 2005. https:\/\/doi.org\/10.2165\/00003495-200565150-00003.","journal-title":"Drugs"},{"issue":"6","key":"4126_CR24","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1172\/jci82981","volume":"126","author":"R Raphemot","year":"2016","unstructured":"Raphemot R, Posfai D, Derbyshire ER. \u201cCurrent therapies and future possibilities for drug development against liver-stage malaria,.\u201d J Clin Invest. 2016;126(6):2013\u201320. https:\/\/doi.org\/10.1172\/jci82981.","journal-title":"J Clin Invest"},{"issue":"1","key":"4126_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-11239-0","volume":"10","author":"G Camarda","year":"2019","unstructured":"Camarda G, et al. \u201cAntimalarial activity of primaquine operates via a two-step biochemical relay,.\u201d Nat Commun. 2019;10(1):1\u20139. https:\/\/doi.org\/10.1038\/s41467-019-11239-0.","journal-title":"Nat Commun"},{"key":"4126_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-418","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014. https:\/\/doi.org\/10.1186\/1475-2875-13-418.","journal-title":"Malar J"},{"key":"4126_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-418","volume":"11","author":"NJ White","year":"2012","unstructured":"White NJ, Qiao LG, Qi G, Luzzatto L. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common,. Malar J. 2012;11:418. https:\/\/doi.org\/10.1186\/1475-2875-11-418.","journal-title":"Malar J"},{"key":"4126_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijpddr.2021.06.003","volume":"17","author":"SS Ahmad","year":"2021","unstructured":"Ahmad SS, Rahi M, Ranjan V, Sharma A. Mefloquine as a prophylaxis for malaria needs to be revisited,. Int J Parasitol Drugs Drug Resist. 2021;17:23\u20136. https:\/\/doi.org\/10.1016\/j.ijpddr.2021.06.003.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"2","key":"4126_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168780","volume":"12","author":"SJ Lee","year":"2017","unstructured":"Lee SJ, Ter Kuile FO, Price RN, Luxemburger C, Nosten F. Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: a pooled analysis of 19, 850 individual patients,. PLoS One. 2017;12(2):e0168780. https:\/\/doi.org\/10.1371\/journal.pone.0168780.","journal-title":"PLoS One"},{"issue":"1","key":"4126_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4269\/AJTMH.16-0390","volume":"96","author":"AA Eick-Cost","year":"2017","unstructured":"Eick-Cost AA, Hu Z, Rohrbeck P, Clark LL. Neuropsychiatric outcomes after mefloquine exposure among U.S. military service members. Am J Trop Med Hyg. 2017;96(1):159\u201366. https:\/\/doi.org\/10.4269\/AJTMH.16-0390.","journal-title":"Am J Trop Med Hyg"},{"key":"4126_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/10408444.2021.1901258","author":"AC Martins","year":"2021","unstructured":"Martins AC, et al. Review of the mechanism underlying mefloquine-induced neurotoxicity,. Crit Rev Toxicol. 2021. https:\/\/doi.org\/10.1080\/10408444.2021.1901258.","journal-title":"Crit Rev Toxicol"},{"issue":"12","key":"4126_CR32","doi-asserted-by":"publisher","first-page":"5344","DOI":"10.1128\/AAC.00790-10","volume":"54","author":"L Carvalho","year":"2010","unstructured":"Carvalho L, Luque-Ortega JR, Manzano JI, Castanys S, Rivas L, Gamarro F. Tafenoquine, an antiplasmodial 8-aminoquinoline, targets Leishmania respiratory complex III and induces apoptosis,. Antimicrob Agents Chemother. 2010;54(12):5344\u201351. https:\/\/doi.org\/10.1128\/AAC.00790-10.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"4126_CR33","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/bcp.12160","volume":"76","author":"AK Miller","year":"2013","unstructured":"Miller AK, et al. Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects,. Br J Clin Pharmacol. 2013;76(6):858\u201367. https:\/\/doi.org\/10.1111\/bcp.12160.","journal-title":"Br J Clin Pharmacol"},{"key":"4126_CR34","unstructured":"\u201cTafenoquine: uses, interactions, mechanism of action | DrugBank Online.\u201d. [Online]. Available:\u00a0https:\/\/go.drugbank.com\/drugs\/DB06608. Accessed 08 Nov 2025."},{"key":"4126_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101908","volume":"39","author":"JD Maier","year":"2021","unstructured":"Maier JD, et al. Efficacy and safety of tafenoquine for malaria chemoprophylaxis (1998\u20132020): a systematic review and meta-analysis. Travel Med Infect Dis. 2021;39:101908. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101908.","journal-title":"Travel Med Infect Dis"},{"key":"4126_CR36","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2011.10-0285","author":"KR Tan","year":"2011","unstructured":"Tan KR, Magill AJ, Parise ME, Arguin PM. Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis. Am J Trop Med Hyg. 2011. https:\/\/doi.org\/10.4269\/ajtmh.2011.10-0285.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"4126_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1086\/516281","volume":"26","author":"SL Andersen","year":"1998","unstructured":"Andersen SL, et al. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in Western Kenya. Clin Infect Dis. 1998;26(1):146\u201350. https:\/\/doi.org\/10.1086\/516281.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"4126_CR38","doi-asserted-by":"publisher","first-page":"963","DOI":"10.7326\/0003-4819-126-12-199706150-00006","volume":"126","author":"C Ohrt","year":"1997","unstructured":"Ohrt C, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997;126(12):963\u201372. https:\/\/doi.org\/10.7326\/0003-4819-126-12-199706150-00006.","journal-title":"Ann Intern Med"},{"key":"4126_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2010.05.005","author":"V Barton","year":"2010","unstructured":"Barton V, Fisher N, Biagini GA, Ward SA, O\u2019Neill PM. Inhibiting Plasmodium cytochrome bc1: a complex issue. Curr Opin Chem Biol. 2010. https:\/\/doi.org\/10.1016\/j.cbpa.2010.05.005.","journal-title":"Curr Opin Chem Biol"},{"issue":"1","key":"4126_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/00019048-200101000-00013","volume":"10","author":"P Pham","year":"2001","unstructured":"Pham P. Atovaquone\/Proguanil. Infect Dis Clin Pract. 2001;10(1):53. https:\/\/doi.org\/10.1097\/00019048-200101000-00013.","journal-title":"Infect Dis Clin Pract"},{"issue":"6","key":"4126_CR41","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1128\/aac.43.6.1334","volume":"43","author":"IK Srivastava","year":"1999","unstructured":"Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother. 1999;43(6):1334\u20139. https:\/\/doi.org\/10.1128\/aac.43.6.1334.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"4126_CR42","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0035-9203(01)90206-8","volume":"95","author":"JD Berman","year":"2001","unstructured":"Berman JD, et al. Causal prophylactic efficacy of atovaquone-proguanil (MalaroneTM) in a human challenge model. Trans R Soc Trop Med Hyg. 2001;95(4):429\u201332. https:\/\/doi.org\/10.1016\/S0035-9203(01)90206-8.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"9245","key":"4126_CR43","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/S0140-6736(00)03260-8","volume":"356","author":"B H\u00f8gh","year":"2000","unstructured":"H\u00f8gh B, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Lancet. 2000;356(9245):1888\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(00)03260-8.","journal-title":"Lancet"},{"issue":"2","key":"4126_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1046\/J.1472-8206.2003.00166.X","volume":"17","author":"J Dupouy-Camet","year":"2003","unstructured":"Dupouy-Camet J, Yera H, Tourte-Schaeffer C. Problems in prescribing malaria chemoprophylaxis for travelers. Fundam Clin Pharmacol. 2003;17(2):161\u20139. https:\/\/doi.org\/10.1046\/J.1472-8206.2003.00166.X.","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"4126_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/S12936-020-3104-4","volume":"19","author":"J Ahluwalia","year":"2020","unstructured":"Ahluwalia J, Brooks SK, Weinman J, Rubin GJ. A systematic review of factors affecting adherence to malaria chemoprophylaxis amongst travellers from non-endemic countries. Malar J. 2020;19(1):16. https:\/\/doi.org\/10.1186\/S12936-020-3104-4.","journal-title":"Malar J"},{"issue":"2","key":"4126_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148627","volume":"11","author":"S Dierickx","year":"2016","unstructured":"Dierickx S, et al. Factors associated with non-participation and non-adherence in directly observed mass drug administration for malaria in the Gambia. PLoS One. 2016;11(2):e0148627. https:\/\/doi.org\/10.1371\/journal.pone.0148627.","journal-title":"PLoS One"},{"key":"4126_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.05.022","author":"DH Surve","year":"2020","unstructured":"Surve DH, Jindal AB. Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs. J Control Release. 2020. https:\/\/doi.org\/10.1016\/j.jconrel.2020.05.022.","journal-title":"J Control Release"},{"key":"4126_CR48","doi-asserted-by":"publisher","unstructured":"Bellinger AM,\u00a0et al.\u00a0\u201cOral, ultra-long-lasting drug delivery: Application toward malaria elimination goals\u201d.\u00a0Sci Transl Med. 2016;8(365).\u00a0https:\/\/doi.org\/10.1126\/scitranslmed.aag2374.","DOI":"10.1126\/scitranslmed.aag2374"},{"issue":"1","key":"4126_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02603-z","volume":"9","author":"RP Bakshi","year":"2018","unstructured":"Bakshi RP, et al. Long-acting injectable atovaquone nanomedicines for malaria prophylaxis. Nat Commun. 2018;9(1):315. https:\/\/doi.org\/10.1038\/s41467-017-02603-z.","journal-title":"Nat Commun"},{"key":"4126_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106795","volume":"198","author":"D Karunakaran","year":"2024","unstructured":"Karunakaran D, et al. Long-acting intramuscular injections of ELQ-331, an antimalarial agent. Eur J Pharm Sci. 2024;198:106795. https:\/\/doi.org\/10.1016\/j.ejps.2024.106795.","journal-title":"Eur J Pharm Sci"},{"key":"4126_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-018-2872-y","author":"CJ Chaccour","year":"2018","unstructured":"Chaccour CJ, et al. Targeting cattle for malaria elimination: marked reduction of Anopheles arabiensis survival for over six months using a slow-release ivermectin implant formulation. Parasit Vectors. 2018. https:\/\/doi.org\/10.1186\/s13071-018-2872-y.","journal-title":"Parasit Vectors"},{"key":"4126_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120820","volume":"605","author":"AR Bhide","year":"2021","unstructured":"Bhide AR, Jindal AB. Fabrication and evaluation of artemether loaded polymeric nanorods obtained by mechanical stretching of nanospheres. Int J Pharm. 2021;605:120820. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120820.","journal-title":"Int J Pharm"},{"key":"4126_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122813","author":"Y Fan","year":"2022","unstructured":"Fan Y, et al. Preliminary assessment of intramuscular depot of lipid-based decoquinate formulation for long-term chemoprophylaxis of malaria. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14122813.","journal-title":"Pharmaceutics"},{"issue":"12","key":"4126_CR54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejpb.2017.11.002","volume":"123","author":"S Dawre","year":"2018","unstructured":"Dawre S, Pathak S, Sharma S, Devarajan PV. Enhanced antimalalarial activity of a prolonged release in situ gel of arteether\u2013lumefantrine in a murine model. Eur J Pharm Biopharm. 2018;123(12):95\u2013107. https:\/\/doi.org\/10.1016\/j.ejpb.2017.11.002.","journal-title":"Eur J Pharm Biopharm"},{"issue":"31","key":"4126_CR55","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1016\/S0264-410X(01)00192-X","volume":"19","author":"JE Rosas","year":"2001","unstructured":"Rosas JE, et al. Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66. Vaccine. 2001;19(31):4445\u201351. https:\/\/doi.org\/10.1016\/S0264-410X(01)00192-X.","journal-title":"Vaccine"},{"key":"4126_CR56","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jconrel.2021.03.036","volume":"333","author":"F Volpe-Zanutto","year":"2021","unstructured":"Volpe-Zanutto F, et al. Artemether and lumefantrine dissolving microneedle patches with improved pharmacokinetic performance and antimalarial efficacy in mice infected with Plasmodium yoelii. J Control Release. 2021;333:298\u2013315. https:\/\/doi.org\/10.1016\/j.jconrel.2021.03.036.","journal-title":"J Control Release"},{"key":"4126_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114862","author":"AB Jindal","year":"2023","unstructured":"Jindal AB, Bhide AR, Salave S, Rana D, Benival D. Long-acting parenteral drug delivery systems for the treatment of chronic diseases. Adv Drug Deliv Rev. 2023. https:\/\/doi.org\/10.1016\/j.addr.2023.114862.","journal-title":"Adv Drug Deliv Rev"},{"key":"4126_CR58","doi-asserted-by":"publisher","unstructured":"Gupta AK,\u00a0et al.\u00a0\u201cA prodrug strategy to reposition atovaquone as a long-acting injectable for malaria chemoprotection.\u201d bioRxiv Prepr Serv Biol. 2024;2024.02.08.579395. https:\/\/doi.org\/10.1101\/2024.02.08.579395.","DOI":"10.1101\/2024.02.08.579395"},{"key":"4126_CR59","doi-asserted-by":"publisher","unstructured":"Kotla NG, Validi S, Ramazani F. Oil-based long-acting injectable systems: Formulation insights and future perspectives. In: Biodegradable Long Acting Injectables and Implants: An Industry View. Cham: Springer; 2025. p. 173\u201384. https:\/\/doi.org\/10.1007\/978-3-031-72302-5_6.","DOI":"10.1007\/978-3-031-72302-5_6"},{"key":"4126_CR60","doi-asserted-by":"publisher","unstructured":"Lee WW, Patterson CM. Biopharmaceutics of Injectable Formulations. In: Biopharmaceutics: From Fundamentals to Industrial Practice. Wiley; 2021. p. 253\u201363. https:\/\/doi.org\/10.1002\/9781119678366.ch15.","DOI":"10.1002\/9781119678366.ch15"},{"issue":"10","key":"4126_CR61","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1021\/acsinfecdis.7b00062","volume":"3","author":"L Frueh","year":"2017","unstructured":"Frueh L, et al. Alkoxycarbonate ester prodrugs of preclinical drug candidate ELQ-300 for prophylaxis and treatment of malaria. ACS Infect Dis. 2017;3(10):728\u201335. https:\/\/doi.org\/10.1021\/acsinfecdis.7b00062.","journal-title":"ACS Infect Dis"},{"issue":"15","key":"4126_CR62","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/S0264-410X(96)00074-6","volume":"14","author":"Y Men","year":"1996","unstructured":"Men Y, Gander B, Merkle HP, Corradin G. Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres. Vaccine. 1996;14(15):1442\u201350. https:\/\/doi.org\/10.1016\/S0264-410X(96)00074-6.","journal-title":"Vaccine"},{"issue":"5","key":"4126_CR63","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/00034983.1981.11687474","volume":"75","author":"RE Howells","year":"1981","unstructured":"Howells RE, Judge BM. Sustained-release implants in the chemotherapy of experimental rodent malaria I: a comparison of the effects of some antimalarials in polydimethylsiloxane matrices. Ann Trop Med Parasitol. 1981;75(5):495\u2013510. https:\/\/doi.org\/10.1080\/00034983.1981.11687474.","journal-title":"Ann Trop Med Parasitol"},{"key":"4126_CR64","doi-asserted-by":"publisher","unstructured":"Liu X,\u00a0et al.\u00a0\u201cAn injectable oil-based depot formulation of N-Acyloxymethyl prodrug of Ropivacaine for Long-Acting Local Analgesia: formulation development and in vitro\/in vivo evaluation,\u201d.\u00a0Pharmaceutics. 2025;17(1).\u00a0https:\/\/doi.org\/10.3390\/pharmaceutics17010037.","DOI":"10.3390\/pharmaceutics17010037"},{"key":"4126_CR65","doi-asserted-by":"publisher","unstructured":"Wright JC, Sekar M, van Osdol W, Su HC, Miksztal AR. In Situ Forming Systems (Depots). In: Long Acting Injections and Implants. Boston, MA: Springer; 2012. p. 153\u201366. https:\/\/doi.org\/10.1007\/978-1-4614-0554-2_9.","DOI":"10.1007\/978-1-4614-0554-2_9"},{"key":"4126_CR66","doi-asserted-by":"publisher","unstructured":"Kempe S, M\u00e4der K. In situ forming implants - an attractive formulation principle for parenteral depot formulations. J Control Release. 2012(2). https:\/\/doi.org\/10.1016\/j.jconrel.2012.04.016.","DOI":"10.1016\/j.jconrel.2012.04.016"},{"key":"4126_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00846","volume":"11","author":"J Golenser","year":"2020","unstructured":"Golenser J, et al. Treatment of experimental cerebral malaria by slow release of Artemisone from injectable pasty formulation. Front Pharmacol. 2020;11:532486. https:\/\/doi.org\/10.3389\/fphar.2020.00846.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4126_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-022-05621-z","volume":"16","author":"SH Pooda","year":"2023","unstructured":"Pooda SH, et al. Proof-of-concept study for a long-acting formulation of ivermectin injected in cattle as a complementary malaria vector control tool. Parasit Vectors. 2023;16(1):66. https:\/\/doi.org\/10.1186\/s13071-022-05621-z.","journal-title":"Parasit Vectors"},{"issue":"1","key":"4126_CR69","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1021\/acs.molpharmaceut.2c00507","volume":"20","author":"AR Bhide","year":"2023","unstructured":"Bhide AR, et al. Evaluation of pharmacokinetics, biodistribution, and antimalarial efficacy of artemether-loaded polymeric nanorods. Mol Pharm. 2023;20(1):118\u201327. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00507.","journal-title":"Mol Pharm"},{"issue":"1","key":"4126_CR70","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijpharm.2008.07.032","volume":"364","author":"M Joshi","year":"2008","unstructured":"Joshi M, Pathak S, Sharma S, Patravale V. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject. Int J Pharm. 2008;364(1):119\u201326. https:\/\/doi.org\/10.1016\/j.ijpharm.2008.07.032.","journal-title":"Int J Pharm"},{"key":"4126_CR71","doi-asserted-by":"publisher","unstructured":"Hedaya MA. \u201cRoutes of drug administration,\u201d. In:\u00a0Pharmaceutics: basic principles and application to pharmacy practice, 3rd ed.\u00a0Vol. 31, no. 5, Academic Press; 2023. p. 537\u2013554. https:\/\/doi.org\/10.1016\/B978-0-323-99796-6.00006-0.","DOI":"10.1016\/B978-0-323-99796-6.00006-0"},{"key":"4126_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s44222-024-00161-w","author":"L Tomasini","year":"2024","unstructured":"Tomasini L, Ferrere M, Nicolas J. Subcutaneous drug delivery from nanoscale systems. Nat Rev Bioeng. 2024. https:\/\/doi.org\/10.1038\/s44222-024-00161-w.","journal-title":"Nat Rev Bioeng"},{"issue":"4","key":"4126_CR73","doi-asserted-by":"publisher","first-page":"4","DOI":"10.25259\/ajbps_14_2023","volume":"3","author":"CE Agbo","year":"2023","unstructured":"Agbo CE, Chima UE, Ogbobe SC, Omotayo FO, David SC. Transdermal antimalarial drug delivery to improve poor adherence to antimalarials: a new light at the end of the tunnel. Am J Biopharmacy Pharm Sci. 2023;3(4):4. https:\/\/doi.org\/10.25259\/ajbps_14_2023.","journal-title":"Am J Biopharmacy Pharm Sci"},{"key":"4126_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1504","author":"MR Prausnitz","year":"2008","unstructured":"Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008. https:\/\/doi.org\/10.1038\/nbt.1504.","journal-title":"Nat Biotechnol"},{"key":"4126_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2013.11.014","author":"MB Delgado-Charro","year":"2014","unstructured":"Delgado-Charro MB, Guy RH. Effective use of transdermal drug delivery in children. Adv Drug Deliv Rev. 2014. https:\/\/doi.org\/10.1016\/j.addr.2013.11.014.","journal-title":"Adv Drug Deliv Rev"},{"key":"4126_CR76","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ijpddr.2021.05.008","volume":"16","author":"J Zech","year":"2021","unstructured":"Zech J, Dzikowski R, Simantov K, Golenser J, M\u00e4der K. Transdermal delivery of artemisinins for treatment of pre-clinical cerebral malaria. Int J Parasitol Drugs Drug Resist. 2021;16:148\u201354. https:\/\/doi.org\/10.1016\/j.ijpddr.2021.05.008.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"4126_CR77","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02106-20","author":"J Zech","year":"2021","unstructured":"Zech J, Salaymeh N, Hunt NH, M\u00e4der K, Golenser J. Efficient treatment of experimental cerebral malaria by an artemisone-SMEDDS system: impact of application route and dosing frequency. Antimicrob Agents Chemother. 2021. https:\/\/doi.org\/10.1128\/AAC.02106-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"4126_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2025.214586","volume":"180","author":"QK Anjani","year":"2026","unstructured":"Anjani QK, et al. Formulation and evaluation of hydrogel-forming microarray patches for transdermal primaquine and chloroquine delivery in malaria therapy. Biomater Adv. 2026;180:214586. https:\/\/doi.org\/10.1016\/j.bioadv.2025.214586.","journal-title":"Biomater Adv"},{"key":"4126_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.102500","volume":"35","author":"QK Anjani","year":"2025","unstructured":"Anjani QK, et al. Polymeric microarray patches for transdermal delivery of amodiaquine and artesunate: a novel strategy against Plasmodium falciparum. Mater Today Bio. 2025;35:102500. https:\/\/doi.org\/10.1016\/j.mtbio.2025.102500.","journal-title":"Mater Today Bio"},{"key":"4126_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2022.112805","volume":"219","author":"AD Permana","year":"2022","unstructured":"Permana AD, Elim D, Ananda PWR, Zaman HS, Muslimin W, Tunggeng MGR. Enhanced and sustained transdermal delivery of primaquine from polymeric thermoresponsive hydrogels in combination with Dermarollers\u00ae. Colloids Surf B Biointerfaces. 2022;219:112805. https:\/\/doi.org\/10.1016\/j.colsurfb.2022.112805.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"4126_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.parint.2022.102720","volume":"93","author":"NSM Aly","year":"2023","unstructured":"Aly NSM, et al. Formulation and evaluation of the antimalarial N-89 as a transdermal drug candidate. Parasitol Int. 2023;93:102720. https:\/\/doi.org\/10.1016\/j.parint.2022.102720.","journal-title":"Parasitol Int"},{"key":"4126_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS15020484","author":"J Lou","year":"2023","unstructured":"Lou J, et al. Advances in oral drug delivery systems: challenges and opportunities. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15020484.","journal-title":"Pharmaceutics"},{"issue":"4","key":"4126_CR83","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s13346-015-0237-z","volume":"5","author":"REM Lutton","year":"2015","unstructured":"Lutton REM, Moore J, Larra\u00f1eta E, Ligett S, Woolfson AD, Donnelly RF. Microneedle characterisation: the need for universal acceptance criteria and GMP specifications when moving towards commercialisation. Drug Deliv Transl Res. 2015;5(4):313\u201331. https:\/\/doi.org\/10.1007\/s13346-015-0237-z.","journal-title":"Drug Deliv Transl Res"},{"key":"4126_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/mi12111321","author":"M Avcil","year":"2021","unstructured":"Avcil M, \u00c7elik A. Microneedles in drug delivery: progress and challenges. Micromachines. 2021. https:\/\/doi.org\/10.3390\/mi12111321.","journal-title":"Micromachines"},{"key":"4126_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e17488","author":"TC Ezike","year":"2023","unstructured":"Ezike TC, et al. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17488.","journal-title":"Heliyon"},{"key":"4126_CR86","unstructured":"Medicine for Malaria Venture. \u201cFirst-ever long-acting injectable for malaria prevention administered to study volunteer.\u201d. [Online]. Available:\u00a0https:\/\/www.mmv.org\/newsroom\/news-resources-search\/first-ever-long-acting-injectable-malaria-prevention-administered. Accessed 02 Dec 2025."},{"issue":"9","key":"4126_CR87","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/nejmoa2034031","volume":"385","author":"MR Gaudinski","year":"2021","unstructured":"Gaudinski MR, et al. A monoclonal antibody for malaria prevention. N Engl J Med. 2021;385(9):803\u201314. https:\/\/doi.org\/10.1056\/nejmoa2034031.","journal-title":"N Engl J Med"},{"issue":"8","key":"4126_CR88","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1038\/s41591-025-03739-y","volume":"31","author":"J Skinner","year":"2025","unstructured":"Skinner J, et al. Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial. Nat Med. 2025;31(8):2682\u201390. https:\/\/doi.org\/10.1038\/s41591-025-03739-y.","journal-title":"Nat Med"},{"key":"4126_CR89","unstructured":"\u201cStudy Details | NCT04329104 | Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali | ClinicalTrials.gov.\u201d [Online]. Available:\u00a0https:\/\/clinicaltrials.gov\/study\/NCT04329104?id=NCT04329104&rank=1.\u00a0Accessed 13 Dec 2025."},{"key":"4126_CR90","doi-asserted-by":"publisher","unstructured":"Lyke KE\u00a0et al.\u00a0\u201cHuman monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial,\u201d Lancet Infect Dis; 2025:0(0).\u00a0https:\/\/doi.org\/10.1016\/s1473-3099(25)00481-5.","DOI":"10.1016\/s1473-3099(25)00481-5"},{"issue":"5","key":"4126_CR91","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/nejmoa2203067","volume":"387","author":"RL Wu","year":"2022","unstructured":"Wu RL, et al. Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria. N Engl J Med. 2022;387(5):397\u2013407. https:\/\/doi.org\/10.1056\/nejmoa2203067.","journal-title":"N Engl J Med"},{"issue":"10","key":"4126_CR92","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S1473-3099(23)00212-8","volume":"23","author":"JL van der Plas","year":"2023","unstructured":"van der Plas JL, et al. Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands. Lancet Infect Dis. 2023;23(10):1164\u201374. https:\/\/doi.org\/10.1016\/S1473-3099(23)00212-8.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"4126_CR93","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/nejmoa2411262","volume":"393","author":"C Chaccour","year":"2025","unstructured":"Chaccour C, et al. Ivermectin to control malaria \u2014 a cluster-randomized trial. N Engl J Med. 2025;393(4):362\u201375. https:\/\/doi.org\/10.1056\/nejmoa2411262.","journal-title":"N Engl J Med"},{"key":"4126_CR94","unstructured":"NCT06558643. \u201cSingle ascending dose study to assess the safety, tolerability and pharmacokinetics of MMV371 LAI in healthy participants,\u201d.\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06558643.\u00a02024. [Online]. Available:\u00a0https:\/\/clinicaltrials.gov\/study\/NCT06558643#participation-criteria. Accessed 19 Dec 2025."},{"key":"4126_CR95","unstructured":"\u201cStudy Details | NCT04206332 | Trial to Evaluate CIS43LS in Healthy Adults | ClinicalTrials.gov.\u201d. [Online]. Available:\u00a0https:\/\/clinicaltrials.gov\/study\/NCT04206332#study-overview. Accessed 19 Dec 2025."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04126-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04126-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04126-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:08:19Z","timestamp":1788541699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04126-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":95,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4126"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04126-z","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}